Galera Therapeutics, Inc. (NASDAQ:GRTX) Short Interest Update

Galera Therapeutics, Inc. (NASDAQ:GRTX) was the target of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 2,660,000 shares, an increase of 50.3% from the March 31st total of 1,770,000 shares. Approximately 6.5% of the shares of the stock are sold short. Based on an average trading volume of 1,950,000 shares, the short-interest ratio is presently 1.4 days.

Galera Therapeutics Trading Down 10.3 %

Galera Therapeutics stock traded down $0.02 during midday trading on Friday, reaching $0.19. 2,268,564 shares of the company were exchanged, compared to its average volume of 2,907,459. The firm’s 50-day simple moving average is $0.20 and its 200-day simple moving average is $0.17. Galera Therapeutics has a 1 year low of $0.09 and a 1 year high of $3.59.

Galera Therapeutics (NASDAQ:GRTX) last posted its quarterly earnings results on Thursday, March 28th. The company reported ($0.10) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Galera Therapeutics

An institutional investor recently bought a new position in Galera Therapeutics stock. abrdn plc bought a new stake in Galera Therapeutics, Inc. (NASDAQ:GRTX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 898,374 shares of the company’s stock, valued at approximately $131,000. abrdn plc owned 1.65% of Galera Therapeutics at the end of the most recent reporting period. 50.77% of the stock is owned by institutional investors.

Galera Therapeutics Company Profile

Galera Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy.